Analyze

Your Database Is Locked. 

Now Make It Count.

Turning raw data into a submission package FDA trusts isn't just execution — it's judgment. Which analyses to run, how to handle anomalies without bias, and how to present results that tell a clear, defensible story.

What we do:

• Data preparation — Systematic screening, population derivation, compliant datasets with full audit trails. Traceable from source to output.

• Statistical analysis — Primary/secondary endpoints, subgroups, sensitivity analyses, DSMB packages, interim monitoring. Frequentist and Bayesian.

• When results surprise you — Missed endpoints and smaller-than-expected effects happen. We assess what the data actually supports and find the strongest defensible story it allows. No spin — rigorous judgment when it matters most.

• TLFs — Validated, SAP-aligned, QC'd against source. Nothing leaves without documentation.

• CSR authorship — Statistical methods, results, interpretation, and limitations — submission-ready through final production.

Why it matters: 

Untraceable derivations, SAP deviations, conclusions that outrun the data — any of these invite FDA questions that delay approval. We operate under 21 CFR Part 11-compliant processes. Our work is documented, reproducible, and built for scrutiny.